2025年7月10日，歐盟食品安全局就一種食品酶β-半乳糖苷酶 （β-galactosidase）的安全性評價發(fā)布意見。
據(jù)了解，這種食品酶是由轉(zhuǎn)基因黑曲霉菌株TOL生產(chǎn)的，旨在用于3種食品生產(chǎn)過程。
經(jīng)過評估，專家小組得出結(jié)論，這種食品酶在預期使用條件下不會引起安全問題。部分原文報道如下：
The food enzyme β-galactosidase (β-d-galactoside galactohydrolase, EC 3.2.1.23) is produced with the genetically modified Aspergillus niger strain TOL by DSM Food Specialties B.V. A safety evaluation of this food enzyme was made previously, in which EFSA concluded that this food enzyme did not give rise to safety concerns when used in one food manufacturing process. Subsequently, the applicant has requested to extend its use to include two additional processes. In the present assessment, EFSA has updated the safety evaluation of this food enzyme when used in a total of three food manufacturing processes. The dietary exposure was calculated to be up to 3.144 mg TOS/kg body weight (bw) per day in European populations. When combined with the no observed adverse effect level previously reported (1038 mg TOS/kg bw per day, the highest dose tested), the Panel derived a margin of exposure of at least 330. based on the revised margin of exposure and the previous evaluation, the Panel concluded that this food enzyme does not give rise to safety concerns under the revised intended conditions of use.
據(jù)了解，這種食品酶是由轉(zhuǎn)基因黑曲霉菌株TOL生產(chǎn)的，旨在用于3種食品生產(chǎn)過程。
經(jīng)過評估，專家小組得出結(jié)論，這種食品酶在預期使用條件下不會引起安全問題。部分原文報道如下：
The food enzyme β-galactosidase (β-d-galactoside galactohydrolase, EC 3.2.1.23) is produced with the genetically modified Aspergillus niger strain TOL by DSM Food Specialties B.V. A safety evaluation of this food enzyme was made previously, in which EFSA concluded that this food enzyme did not give rise to safety concerns when used in one food manufacturing process. Subsequently, the applicant has requested to extend its use to include two additional processes. In the present assessment, EFSA has updated the safety evaluation of this food enzyme when used in a total of three food manufacturing processes. The dietary exposure was calculated to be up to 3.144 mg TOS/kg body weight (bw) per day in European populations. When combined with the no observed adverse effect level previously reported (1038 mg TOS/kg bw per day, the highest dose tested), the Panel derived a margin of exposure of at least 330. based on the revised margin of exposure and the previous evaluation, the Panel concluded that this food enzyme does not give rise to safety concerns under the revised intended conditions of use.
